临床消化病杂志
臨床消化病雜誌
림상소화병잡지
Chinese Journal of Clinical Gastroenterology
2015年
4期
225-227
,共3页
反流性食管炎%枳术宽中胶囊%质子泵抑制剂
反流性食管炎%枳術寬中膠囊%質子泵抑製劑
반류성식관염%지술관중효낭%질자빙억제제
reflux esophagitis%zhizhukuanzhong capsule%proton pump inhibitors
[目的]观察枳术宽中胶囊联合质子泵抑制剂（PPI）治疗反流性食管炎的临床效果。[方法]将100例反流性食管炎患者随机分为观察组和对照组，每组50例。对照组给予奥美拉唑和西沙必利联合治疗（PPI治疗），奥美拉唑每次20mg，2次／d；西沙必利每次10mg，3次／d，餐前或者睡前服用。观察组在对照组的治疗基础上加服枳术宽中胶囊1.29 g ，口服，3次／d。比较2组治疗前、后临床症状及治疗8周后的临床疗效。[结果]经治疗，2组患者临床症状均较治疗前明显缓解。治疗4周后，2组患者的烧心症状积分比较，差异无统计学意义（P＞0.05），观察组的反酸和胸骨后疼痛症状积分明显优于对照组（P＜0.01）；治疗6周、8周以及停药2周后，观察组的反酸、烧心、胸骨后疼痛症状均优于对照组，差异有统计学意义（P＜0.01）；观察组疗效明显优于对照组，差异有统计学意义（P＜0.05）。[结论]枳术宽中胶囊联合PPI治疗反流性食管炎安全有效，且无明显不良反应，值得临床推广。
[目的]觀察枳術寬中膠囊聯閤質子泵抑製劑（PPI）治療反流性食管炎的臨床效果。[方法]將100例反流性食管炎患者隨機分為觀察組和對照組，每組50例。對照組給予奧美拉唑和西沙必利聯閤治療（PPI治療），奧美拉唑每次20mg，2次／d；西沙必利每次10mg，3次／d，餐前或者睡前服用。觀察組在對照組的治療基礎上加服枳術寬中膠囊1.29 g ，口服，3次／d。比較2組治療前、後臨床癥狀及治療8週後的臨床療效。[結果]經治療，2組患者臨床癥狀均較治療前明顯緩解。治療4週後，2組患者的燒心癥狀積分比較，差異無統計學意義（P＞0.05），觀察組的反痠和胸骨後疼痛癥狀積分明顯優于對照組（P＜0.01）；治療6週、8週以及停藥2週後，觀察組的反痠、燒心、胸骨後疼痛癥狀均優于對照組，差異有統計學意義（P＜0.01）；觀察組療效明顯優于對照組，差異有統計學意義（P＜0.05）。[結論]枳術寬中膠囊聯閤PPI治療反流性食管炎安全有效，且無明顯不良反應，值得臨床推廣。
[목적]관찰지술관중효낭연합질자빙억제제（PPI）치료반류성식관염적림상효과。[방법]장100례반류성식관염환자수궤분위관찰조화대조조，매조50례。대조조급여오미랍서화서사필리연합치료（PPI치료），오미랍서매차20mg，2차／d；서사필리매차10mg，3차／d，찬전혹자수전복용。관찰조재대조조적치료기출상가복지술관중효낭1.29 g ，구복，3차／d。비교2조치료전、후림상증상급치료8주후적림상료효。[결과]경치료，2조환자림상증상균교치료전명현완해。치료4주후，2조환자적소심증상적분비교，차이무통계학의의（P＞0.05），관찰조적반산화흉골후동통증상적분명현우우대조조（P＜0.01）；치료6주、8주이급정약2주후，관찰조적반산、소심、흉골후동통증상균우우대조조，차이유통계학의의（P＜0.01）；관찰조료효명현우우대조조，차이유통계학의의（P＜0.05）。[결론]지술관중효낭연합PPI치료반류성식관염안전유효，차무명현불량반응，치득림상추엄。
Objective]The clinical efficacy of Zhizhukuanzhong capsule combined with proton pump in‐hibitors(PPIs)therapy on 50 cases of reflux esophagitis were observed. [Methods]One hundred cases of re‐flux esophagitis in our hospital were randomly divided into observation group and control group with 50 ca‐ses in each group. The cases in control group received omeprazole and cisapride combination therapy. The cases in observation group received an additional Zhizhukuanzhong capsule treatment. A course of treat‐ment in both groups were 8 weeks. The clinical efficacy of two groups were compared. [Results]The clinical symptoms were significantly alleviated. The difference of symptoms scores of acid reflux ,heartburn ,chest burning before treatment was not statistically significant (P> 0.05)in both groups.After 4 weeks treat‐ment ,the symptom score of heartburn was not different between the two groups. The symptom scores of acid reflux and chest pain in the observation group was significantly lower than the control group.At the 6 weeks ,8 weeks and 2 weeks after discontinuation ,the symptoms scores of acid reflux ,heartburn ,chest pain in observation group were significantly lower than the control group (P< 0.01). [Conclusion]Zhizhuku‐anzhong capsule combined with PPI shows safe ,effective ,and no significant adverse reactions on the treat‐ment of reflux esophagitis ,which is worthy of promotion.
